AQST SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 3, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 13, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 4, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Aquestive Therapeutics Reports Corporate Presentation Highlights and Cash Position for November 2026

Nov 5, 2026

8-K

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Nov 3, 2026

8-K

Aquestive Therapeutics Adopts Amended and Restated Bylaws

Oct 19, 2026

8-K

Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027

Oct 15, 2026

8-K

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

Oct 14, 2026

8-K

Aquestive Therapeutics Appoints Richard Daly to Board of Directors

Sep 29, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

SHARE RESALE REGISTRATION | Shares: 230,271

Jul 9, 2026

424B5

REGISTERED OFFERING

Aug 14, 2025

424B2

TABLE OF CONTENTS Up to $100,000,000 Common Stock PROSPECTUS Piper Sandler April 23, 2024

Apr 24, 2024

424B2

Common Stock

Apr 24, 2024

424B5

OFFERING | Shares amount: 16,666,667 | Share price: $4.50 | Offering amount: $75,000,002.00

Mar 21, 2024

424B5

PENDING OFFERING | Share price: $5.51

Mar 19, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-3

SHARE RESALE REGISTRATION

Jun 26, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 4, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jan 21, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jan 24, 2025

S-3

SHELF | ATM | Offering amount: $250,000,000.00 EFFECTIVE

Apr 3, 2024

S-8

Registration

Feb 12, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 24, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 24, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 25, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 25, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 26, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 26, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Jul 9, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 24, 2024

CORRESP

Form CORRESP - Correspondence

Apr 19, 2024

CORRESP

Form CORRESP - Correspondence

Apr 19, 2024

CORRESP

Form CORRESP - Correspondence

Apr 16, 2024

LETTER

Form UPLOAD - SEC-generated letter

Apr 8, 2024

Aquestive Therapeutics, Inc. AQST · SEC Filings